RD
RDTCF.US Rapid Dose Therapeutics Corp
- Market cap
- USD 7.88M
- P/E
- -
- P/B
- 29.59x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Aug 2026.
Is RDTCF.US undervalued?
Graham numberThe Graham number of Rapid Dose Therapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rapid Dose Therapeutics Corp fundamental analysis
No fundamental analysis for Rapid Dose Therapeutics Corp yet.
Rapid Dose Therapeutics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system designed to rapidly release pharmaceuticals, emulsified oils, and over-the-counter medicines into the bloodstream. It also provides over-the-counter products consisting of QuickStrip Energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12; and QuickStrip Sleep to del…
Full company profileRapid Dose Therapeutics Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rapid Dose Therapeutics Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 0.00 | 101K | 755K | 1.75M | 718K | 1.02M | 2.09M | 2.77M | 1.61M |
| Gross Profit | - | - | -156K | 37.3K | 700K | 1.35M | 372K | 563K | 1.18M | 1.36M | -1.02M |
| Operating Income | -47.1K | -50.1K | -11.5M | -7.61M | -1.78M | -4.44M | -3.81M | -3.74M | 5.40M | -1.66M | -1.51M |
| EBITDA | -47.1K | -50.1K | -11.3M | -7.37M | -987K | -7.59M | -2.92M | -3.03M | -3.93M | -1.66M | -1.03M |
| Net Income | -47.1K | -50.1K | -11.4M | -7.97M | -1.81M | -8.49M | -3.81M | -4.31M | -5.40M | -3.39M | -2.62M |
| EPS | -0.06 | 0.00 | -0.18 | -0.10 | -0.02 | -0.08 | -0.04 | -0.04 | -0.04 | -0.03 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 903.00 | 17.1K | 5.78M | 4.29M | 3.83M | 3.07M | 2.25M | 1.89M | 1.63M | 3.28M | 2.93M |
| Total Liabilities | 37.8K | 29.8K | 1.96M | 4.44M | 4.92M | 2.82M | 4.92M | 5.04M | 6.84M | 10.5M | 11.2M |
| Shareholders' Equity | -36.8K | -12.8K | 3.83M | -148K | -1.09M | 252K | -2.67M | -3.16M | -5.21M | -7.18M | -8.22M |
| Cash & Short-term Investments | 903.00 | 17.1K | 3.49M | 3.47K | 70.3K | 34.4K | 27.6K | 161K | 20.7K | 11.6K | 8.65K |
| Total Debt | - | - | - | 1.22M | 2.06M | 1.17M | 1.80M | 2.25M | 2.61M | 5.13M | 5.40M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -30.7K | -58.0K | -2.13M | -3.03M | -1.62M | -3.00M | -864K | -2.29M | -1.15M | -270K | 67.4K |
| Capital Expenditure | 0.00 | 208K | 1.67M | 1.22M | 9.12K | 40.4K | 0.00 | 0.00 | 5.74K | 895.00 | 8.28 |
| Free Cash Flow | -30.7K | -266K | -3.80M | -4.26M | -1.63M | -3.04M | -864K | -2.29M | -1.15M | -271K | 67.4K |
| Ratios | |||||||||||
| ROE | - | - | -297.8% | - | - | -3,373.7% | - | - | - | - | - |
| ROA | -5,215.6% | -293.5% | -197.1% | -185.7% | -47.1% | -276.6% | -169.6% | -228.4% | -330.5% | -103.3% | -89.3% |
| Net Profit Margin | - | - | - | -7,847.4% | -239.0% | -484.4% | -530.4% | -422.2% | -259.2% | -122.2% | -163.0% |
| Debt to Equity | - | - | - | - | - | 4.67x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rapid Dose Therapeutics Corp dividends
Rapid Dose Therapeutics Corp has not paid dividends in the last 9 fiscal years.
Who owns Rapid Dose Therapeutics Corp
- Insiders 17.02%
- Institutions 0.00%
- Public & others 82.98%
- Shares outstanding 138M
- Free float 117M
Rapid Dose Therapeutics Corp company profile
- Company name
- Rapid Dose Therapeutics Corp
- Ticker
- RDTCF.US
- ISIN
- CA75339A1012
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- February
- Address
- 1121 Walker's Line, Burlington, ON, Canada, L7N 2G4
- Phone
- 416-477-1052
- Website
- rapid-dose.com
About Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system designed to rapidly release pharmaceuticals, emulsified oils, and over-the-counter medicines into the bloodstream. It also provides over-the-counter products consisting of QuickStrip Energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12; and QuickStrip Sleep to deliver melatonin, as well as dental products including Lidocaine QuickStrip, a muco-adhesive oral thin film. It also engages in the research, production, provision, and distribution of technical services for the delivery of oral thin film strips containing active ingredients. In addition, the company is involved in the sale of health and wellness products, such as nutraceuticals; white label manufacturing, including oral thin film strips containing active ingredients under cannabis licensing; and the provision of consulting services for the application of active ingredients with the oral thin film polymer formulation and processes. Rapid Dose Therapeutics Corp. is headquartered in Burlington, Canada.
Rapid Dose Therapeutics Corp management
8- Mr. Mark Andrew UpsdellFounder, President, CEO & Director
- Mr. Douglas Alan Hyland C.A., CPAChief Financial Officer
- Mr. Jason LewisSenior VP of Business Development & Director
- Paula MacBethDirector of Operations
- Mr. Donald Alexander-R. Sheldon B.A.Sc., L.L.B., M.A.Sc., P.Eng.Legal Counsel · born 1947
- Ms. Nissrine GhannoumDirector of Marketing & Communications
- Rishi KapadiaController
- Jorge EstepaAssistant Corporate Secretary